Skip to content
OpenCapital
Get started

Solid Biosciences Inc. SLDB Q4 2025 Annual earnings

Reported March 19, 2026 · After market close

EPS-$0.50Beat by $0.01
EPS estimate-$0.51

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.43

Financials

Q4 2025

Income statement

See full
Operating income-$49.4M-23.8%
Net income-$49.8M-16.9%
EPS (diluted)-$0.53+48.0%

Balance sheet

See full
Cash & equivalents$59.9M-25.3%
Total debt$21.2M-12.5%
Total equity$180.0M+31.2%
Total assets$232.5M+23.3%

Cash flow

See full
Operating cash flow-$53.6M-80.7%
CapEx$565.0K+177%
Free cash flow-$54.1M-81.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$439.41M+175%
Enterprise value$400.67M+286%

Returns & leverage

See full
Return on equity-109.9%+21.3pp
Debt / equity0.1×-0.1×
Current ratio6.1×+0.9×

Versus estimates

Diluted EPS

Q1 2026-$0.52Miss by $0.12
Q4 2025-$0.50Beat by $0.01
Q3 2025-$0.48Miss by $0.06Q2 2025-$0.42Beat by $0.09Q1 2025-$0.59Miss by $0.06Q4 2024-$0.89Miss by $0.10

Ask the moment Solid Biosciences Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Solid Biosciences Inc. report Q4 2025 earnings?
Solid Biosciences Inc. (SLDB) reported Q4 2025 earnings on March 19, 2026 after market close.
What were Solid Biosciences Inc.'s Q4 2025 revenue and EPS?
Solid Biosciences Inc. reported eps of $-0.50 for Q4 2025.
Did Solid Biosciences Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.51 by $0.01.
How did Solid Biosciences Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 43.8% from $-0.89.
Where can I find Solid Biosciences Inc.'s Q4 2025 SEC filings?
You can read the 10-K periodic report (0001193125-26-115928) directly on SEC EDGAR. The filing index links above go to sec.gov.